January 2026 in “Biomaterials Science” The formulation helps improve wound healing and skin repair.
53 citations
,
July 1981 in “Journal of Endocrinology” α-MSH and cyclic AMP boost melanin production, while cyclic GMP and melatonin reduce it.
14 citations
,
March 2023 in “Bioengineering” Standardized PRP is effective for tendinopathies, with most patients improving after one injection.
21 citations
,
February 2023 in “Bioengineering” Standardizing PRP therapy practices and regulations in Europe is crucial for safe and effective treatment.
2 citations
,
January 2019 in “Applied clinical research, clinical trials and regulatory affairs” Different countries have regulations to ensure the safety of hair care products, with some recalling hair straighteners due to high formaldehyde.
April 2024 in “Current journal of applied science and technology” The organic hair ointment is safe, promotes hair growth in male rabbits, and has good stability and pH for human use.
December 2025 in “Eastern Ukrainian Medical Journal” Standardized protocols are crucial for effective use of platelet-rich plasma and fibrin in tissue regeneration.
November 2025 in “JPRAS Open” Exosome therapy could help with hair loss, but more research and regulation are needed.
September 2017 in “Journal of Investigative Dermatology” Injections of special skin cells showed potential in treating hair loss, with some participants experiencing increased hair density.
86 citations
,
July 1990 in “British Journal of Pharmacology” Diazoxide, minoxidil sulphate, and cromakalim relax rat blood vessels by opening K+ channels, with some differences in their actions.
1 citations
,
January 1981 in “Elsevier eBooks” Melatonin stops melanin production after tyrosinase action, with cyclic GMP mimicking this effect.
May 2026 in “Frontiers in Cell and Developmental Biology” This review discusses the potential of mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) as a cell-free therapy for burn management, focusing on their roles in inflammation regulation, angiogenesis, epithelial regeneration, and ECM remodeling. The authors propose a framework for translating these therapies into clinical practice, highlighting their advantages in addressing inflammation, regeneration, and fibrosis. However, challenges such as donor consistency, GMP compliance, standardization of quality attributes, and optimization of administration strategies need to be addressed. The review emphasizes the importance of establishing standardized production and quality-control systems and conducting multicenter randomized studies to facilitate the translation of MSC/EV therapies from research to clinical application.
29 citations
,
February 2022 in “Frontiers in Cell and Developmental Biology” Improving CRISPR/Cas systems can make gene editing more efficient and precise.
June 2022 in “Authorea (Authorea)” Efficient delivery systems are needed for the clinical use of CRISPR-Cas9 gene editing.
51 citations
,
June 2021 in “Signal Transduction and Targeted Therapy” The document concludes that while there are promising methods to control CRISPR/Cas9 gene editing, more research is needed to overcome challenges related to safety and effectiveness for clinical use.
149 citations
,
August 2022 in “Biochemistry (Moscow)” CRISPR-Cas9 allows precise DNA editing but raises ethical concerns about modifying human embryos.
1 citations
,
April 2023 in “International Journal of Molecular Sciences” New CRISPR/Cas9 variants and nanotechnology-based delivery methods are improving cancer treatment, but choosing the best variant and overcoming certain limitations remain challenges.
June 2024 in “International Journal of Nanomedicine” CRISPR/Cas9 has improved precision and control but still faces clinical challenges.
January 2025 in “Molecules” Non-viral delivery systems and stimuli-responsive nanoformulations can improve CRISPR-Cas9 gene therapy.
7 citations
,
August 2022 in “Journal of Nanobiotechnology” Advancements in nanoformulations for CRISPR-Cas9 genome editing can respond to specific triggers for controlled gene editing, showing promise in treating incurable diseases, but challenges like precision and system design complexity still need to be addressed.
23 citations
,
January 2022 in “Biomaterials Science” Non-viral vectors show promise for safe and effective CRISPR/Cas9 gene editing in treating diseases.
September 2023 in “HAL (Le Centre pour la Communication Scientifique Directe)” Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.
November 2023 in “ACS Omega” New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.
60 citations
,
July 2020 in “ACS Nano” Using CRISPR for gene editing in the body is promising but needs better delivery methods to be more efficient and specific.
4 citations
,
July 2012 in “Genesis” The Megsin-Cre transgene is a new tool for genetic manipulation in the skin and upper digestive tract.
46 citations
,
October 2022 in “Biomaterials”
21 citations
,
January 2022 in “Biomaterials Science” RNA delivery is best for in-body use, while RNP delivery is good for outside-body use. Both methods are expected to greatly impact future treatments.
March 2024 in “Agriculture” CRISPR/Cas9 gene-editing shows promise for improving sheep and goat breeding but faces challenges with efficiency and accuracy.
8 citations
,
June 2024 in “APOPTOSIS” Caspases affect many cell functions and could help treat various diseases.
7 citations
,
January 2023 in “Frontiers in Cell and Developmental Biology” Caspases are enzymes important for both cell death and various non-lethal cell functions, affecting head development and hair growth, with different caspases playing specific roles.